EPICS: Global Perspectives in Gastrointestinal Malignancies in 2022 and Beyond

Latest therapeutic developments in GI cancer treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

July 15 & 18, 2022
Howard Hochster, MD, FACP, Aptitude Health Scientific Leader

Faculty Co-Chair

Howard S. Hochster, MD, FACP

Rutgers Cancer Institute of New Jersey

Gerald Prager MD Aptitude Health 2020 GI

Faculty Co-Chair

Gerald Prager, MD, PhD

University of Vienna, Austria

Faculty Members

Christopher Lieu, MD
University of Colorado Cancer Center, Aurora, CO, USA

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic Cancer Center, Phoenix, AZ, USA

Kristen Ciombor, MD, MSCI
Vanderbilt University, Nashville, TN, USA

Efrat Dotan, MD
Fox Chase Cancer Center, Philadelphia, PA, USA

Robert Glynne-Jones, MBBS, FRCP, FRCR
Mount Vernon Hospital, Northwood, United Kingdom

Julien Taieb, MD, PhD
University of Paris, France

Dirk Arnold, MD, PhD
University of Hamburg, Germany

Talia Golan, MD
Sheba Medical Center, Ramat Gan, Israel

Sample Report

Start discovering the insights

View Report


  • Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments
  • Metastatic Colorectal Cancer – Immunotherapy
  • Hepatocellular Carcinoma
  • Gastroesophageal Junction (GEJ) and Gastric Cancer
  • Rectal Cancer
  • Pancreatic Cancer and Biliary Tract Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.